Illinois Senator Leads New Law to Ban E-cigarette Sales

Aug.13.2024
Illinois Senator Leads New Law to Ban E-cigarette Sales
Illinois Senator Meg Loughran Cappel leads new law banning e-cigarette shipments to protect youth from harm.

According to Patch on August 12th, in order to protect teenagers from the harms of e-cigarettes, Illinois State Senator Meg Loughran Cappel is leading an initiative to ban the shipment of e-cigarettes to Illinois.


The legislator stated that


The internet makes it easy for children to access e-cigarettes. Manufacturers are designing e-cigarettes to look like stationery, making it difficult for teachers to tell if it is an e-cigarette. After hearing from local elected officials about the significant increase in e-cigarette use in schools, we realize that measures must be taken to protect children from the dangers of smoking.


Senate Bill 3098 prohibits the shipment of e-cigarettes purchased through mail, online, or other remote sales methods to any individual in the state of Illinois, unless the recipient is a distributor or retailer.


The legislation introduced by Logan Capell is aimed at addressing students accessing e-cigarettes disguised as everyday items such as highlighters.


The bill was signed into law on Friday (the 9th) and will come into effect on January 1, 2025.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco International (HK) Announces FY2025 Results: Revenue Reaches HK$14.58 Billion, Up 11.5% Year-on-Year
China Tobacco International (HK) Announces FY2025 Results: Revenue Reaches HK$14.58 Billion, Up 11.5% Year-on-Year
China Tobacco International (HK) Company Limited announced its audited results for the year ended December 31, 2025. Revenue was HK$14.58 billion, profit before taxation was HK$1.28 billion, and profit attributable to owners of the Company was HK$0.98 billion, with basic and diluted EPS of HK$1.42. The Board proposed a final dividend of HK$0.33 per share; together with an interim dividend of HK$0.19 per share, the full-year dividend totaled HK$0.52 per share.
Mar.06 by 2FIRSTS.ai
JT Delivers Record FY2025 Results as RRP Accelerates and Ploom Expands Globally
JT Delivers Record FY2025 Results as RRP Accelerates and Ploom Expands Globally
JT reported record FY2025 revenue and adjusted operating profit, supported by combustible resilience and accelerating reduced-risk product growth. Heated tobacco volumes surged, led by Ploom. The group confirmed a major three-year RRP investment plan and projected further growth in 2026.
Feb.12
China Tobacco Hubei Industrial Co., Ltd Tests New Gas Release Nicotine Pouch Technology, According to Patent Documents
China Tobacco Hubei Industrial Co., Ltd Tests New Gas Release Nicotine Pouch Technology, According to Patent Documents
China Tobacco Hubei Industrial Co., Ltd applies for patents on new nicotine pouch technology with gas release feature.
Mar.04 by 2FIRSTS.ai
Alabama Senate Passes SB9 to Ban Vaping in Indoor Public Places
Alabama Senate Passes SB9 to Ban Vaping in Indoor Public Places
Alabama’s Senate approved SB9 by a 31–1 vote, expanding existing indoor smoking restrictions to include vaping in a wide range of public places. The bill keeps the current $25 fine, renames the state’s Clean Indoor Air Act, and now heads to the House. If enacted, it would take effect on Oct. 1, 2026.
Feb.02 by 2FIRSTS.ai
Ohio Supreme Court takes up appeal that could define state limits on illegal vape sales enforcement
Ohio Supreme Court takes up appeal that could define state limits on illegal vape sales enforcement
The Ohio Supreme Court has agreed to hear Attorney General Dave Yost’s appeal seeking to revive lawsuits against three Ohio vape retailers. Lower courts dismissed the cases, finding that federal law governs whether vaping products may be marketed and sold.
Mar.06 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11